GCM
PACB icon

Goldstream Capital Management’s Pacific Biosciences PACB Stock Holding History

Goldstream Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-72,386
Closed -$1.48M – 39
2021
Q4 		$1.48M Buy
+72,386
New +$1.75M 0.36% 29

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldstream Capital Management's PACB Position: Q1 2022 in Review

Goldstream Capital Management sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 72,386 shares — an estimated $1.48M sold.

Goldstream Capital Management first reported a position in PACB in Q4 2021 and held it in 1 quarter. The position peaked at $1.48M in Q4 2021. 250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

  • Goldstream Capital Management reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
  • Goldstream Capital Management sold 72,386 Pacific Biosciences shares in Q1 2022, an estimated $1.48M.
  • Goldstream Capital Management first reported a position in Pacific Biosciences in Q4 2021 and held it in 1 quarter.
  • Goldstream Capital Management's Pacific Biosciences position peaked at $1.48M in Q4 2021.
  • 250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on Goldstream Capital Management's 13F filing for Q1 2022, filed 13 May 2022.